ARCA Biopharma - נכסים נקיים למניה בודדת ABIO

ARCA Biopharma (ABIO) develops targeted treatments for genetic heart failure, leveraging patent protection and final trial results. This book value per share chart illustrates the current state of assets, where 2.26 indicates the level of this metric. The company is currently reorganizing its biotech resources following a merger and accumulating data. A precision therapy approach provides the potential for monopoly pricing power over innovative drugs.

Book value per share is calculated as the ratio of net assets to the total number of common shares, measuring the actual value of capital per share. For ARCA Biopharma (ABIO), whose humanitarian developments are shielded from geopolitical volatility, the book value per share trend confirms steady resource accumulation and the financial stability of the business.